BIOMAT Database Logo BIOMAT Database Logo

In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. 1993

L A Collins, and G J Malanoski, and G M Eliopoulos, and C B Wennersten, and M J Ferraro, and R C Moellering
Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts 02215.

The in vitro activity of RP59500, a streptogramin antibiotic, against 146 clinical isolates of vancomycin-resistant gram-positive bacteria was examined. Five strains of the species Enterococcus casseliflavus and Enterococcus gallinarum, for which the MIC of vancomycin was 8 micrograms/ml, were also studied. Twenty-eight vancomycin-susceptible strains of Enterococcus faecalis and Enterococcus faecium were included for comparison. The drug was highly active against Leuconostoc spp., Lactobacillus spp., and Pediococcus spp. (MICs, < or = 2 micrograms/ml). RP59500 was more active against vancomycin-susceptible strains of E. faecium than E. faecalis (MICs for 90% of the strains [MIC90s], 1.0 versus 32 micrograms/ml). Vancomycin-resistant strains of E. faecalis were as resistant to RP59500 as vancomycin-susceptible strains (MIC90, 32 micrograms/ml), but some vancomycin-resistant E. faecium strains were relatively more resistant to the new agent (MIC90, 16; MIC range, 0.5 to 32 micrograms/ml) than were vancomycin-susceptible organisms of this species.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006094 Gram-Positive Bacteria Bacteria which retain the crystal violet stain when treated by Gram's method. Gram Positive Bacteria
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014640 Vancomycin Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. AB-Vancomycin,Diatracin,VANCO-cell,Vanco Azupharma,Vanco-saar,Vancocin,Vancocin HCl,Vancocine,Vancomicina Abbott,Vancomicina Chiesi,Vancomicina Combino Phar,Vancomicina Norman,Vancomycin Hexal,Vancomycin Hydrochloride,Vancomycin Lilly,Vancomycin Phosphate (1:2),Vancomycin Phosphate (1:2), Decahydrate,Vancomycin Sulfate,Vancomycin-ratiopharm,Vancomycine Dakota,Hydrochloride, Vancomycin,Sulfate, Vancomycin
D014769 Virginiamycin A cyclic polypeptide antibiotic complex from Streptomyces virginiae, S. loidensis, S. mitakaensis, S. pristina-spiralis, S. ostreogriseus, and others. It consists of 2 major components, VIRGINIAMYCIN FACTOR M1 and virginiamycin Factor S1. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry. Staphylomycin,Antibiotic 899,Eskalin,Founderguard,Stajac,Virgimycine
D016983 Enterococcus A genus of gram-positive, coccoid bacteria consisting of organisms causing variable hemolysis that are normal flora of the intestinal tract. Previously thought to be a member of the genus STREPTOCOCCUS, it is now recognized as a separate genus.

Related Publications

L A Collins, and G J Malanoski, and G M Eliopoulos, and C B Wennersten, and M J Ferraro, and R C Moellering
In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.
June 1993, Antimicrobial agents and chemotherapy,
L A Collins, and G J Malanoski, and G M Eliopoulos, and C B Wennersten, and M J Ferraro, and R C Moellering
In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.
January 1997, Chemotherapy,
L A Collins, and G J Malanoski, and G M Eliopoulos, and C B Wennersten, and M J Ferraro, and R C Moellering
In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria.
July 1992, The Journal of antimicrobial chemotherapy,
L A Collins, and G J Malanoski, and G M Eliopoulos, and C B Wennersten, and M J Ferraro, and R C Moellering
In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria.
July 2005, Antimicrobial agents and chemotherapy,
L A Collins, and G J Malanoski, and G M Eliopoulos, and C B Wennersten, and M J Ferraro, and R C Moellering
In vitro activity of cefpirome (HR810) against antibiotic-resistant gram-positive and gram-negative bacteria including organisms with inducible resistance.
January 1986, Diagnostic microbiology and infectious disease,
L A Collins, and G J Malanoski, and G M Eliopoulos, and C B Wennersten, and M J Ferraro, and R C Moellering
Activity of glycopeptides against vancomycin-resistant gram-positive bacteria.
September 1989, Antimicrobial agents and chemotherapy,
L A Collins, and G J Malanoski, and G M Eliopoulos, and C B Wennersten, and M J Ferraro, and R C Moellering
Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
January 2005, Clinical therapeutics,
L A Collins, and G J Malanoski, and G M Eliopoulos, and C B Wennersten, and M J Ferraro, and R C Moellering
Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
September 1997, The Journal of antimicrobial chemotherapy,
L A Collins, and G J Malanoski, and G M Eliopoulos, and C B Wennersten, and M J Ferraro, and R C Moellering
[In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
May 1992, Pathologie-biologie,
L A Collins, and G J Malanoski, and G M Eliopoulos, and C B Wennersten, and M J Ferraro, and R C Moellering
In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
July 2014, The Journal of antibiotics,
Copied contents to your clipboard!